Amgen Inc. Commercial Paper
Amgen Inc. (AMGN) had Commercial Paper of $0 as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:CommercialPaper · last filed 2026-02-13
- 2025-12-31: Commercial Paper $0.00.
- 2024-12-31: Commercial Paper $0.00.
- 2023-12-31: Commercial Paper $0.00.
- 2022-12-31: Commercial Paper $0.00.
| Period end | Commercial Paper |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-14 |
| 2022-12-31 | $0.00 10-K · filed 2024-02-14 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-09 |
| 2017-09-30 | $1.50B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $960.00M 10-Q · filed 2017-07-26 |
| 2016-12-31 | $0.00 10-Q · filed 2017-10-26 |
| 2011-09-30 | $300.00M 10-Q · filed 2011-11-04 |
| 2010-12-31 | $0.00 10-Q · filed 2011-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |